Shield C F, Norman D J
Department of Surgery, University of Kansas, School of Medicine, Wichita.
Am J Kidney Dis. 1988 Feb;11(2):120-4. doi: 10.1016/s0272-6386(88)80193-8.
Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/microL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.
在使用OKT3治疗期间及治疗后6周应进行免疫监测。治疗期间应每周进行三次CD3绝对细胞计数测定。绝对CD3细胞计数逐步增加至高于10/微升提示OKT3血清水平不足，最常见的原因是早期抗鼠反应。应测定治疗后每周的抗鼠反应。抗鼠反应的有无可提示对OKT3第二个疗程治疗的成功反应。
